Search
MSK announces the establishment of The Tow Center for Developmental Oncology (TCDO).
Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, achieved several notable advances in 2024, including earning authorization to provide the first gene therapy for sickle cell disease and beta thalassemia, opening a new program for patients with desmoplastic small round cell tumors, translating groundbreaking tumor evolution insights into a new clinical trial strategy for patients with osteosarcoma, and leading cutting-edge research for improving patient outcomes after CAR T cell therapy.
MSK leads the way in optimizing radiation treatment for breast cancer patients.
Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact [email protected].
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
Lopez was recognized for his positive impact on New York City through his professional, communal, and philanthropic achievements.
Meet MSK Director of Social Work Penny Damaskos and learn how she and her team help people with cancer.
A new type of engineered immune cell could be a potent treatment for cancers that have escaped other immunotherapies.
The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer, results of a large, phase III study show.
Last week, Governor Kathy Hochul signed the New York State Budget for FY 2023 that includes a key provision which will allow more New Yorkers from underserved communities access to care at Memorial Sloan Kettering Cancer Center (MSK) and other NCI-designated cancer centers in the state.